EUA
New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel
FDA Emergency Use Authorization · Wadsworth Center, New York State Department of Public Health · May 20, 2021
Key facts
| Product | New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel |
|---|---|
| Company | Wadsworth Center, New York State Department of Public Health |
| Product type | Real-time RT-PCR, Multiple Targets |
| Date | May 20, 2021 |
| FDA page | fda.gov |
At a glance
- 1–9 Authorization documents
- 1–9 EUAs for this company
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Emergency Use Authorizations
Emergency Use Authorizations allow the FDA to permit unapproved medical products, or unapproved uses of approved products, during a declared public health emergency.
Source: U.S. Food and Drug Administration (FDA), Emergency Use Authorizations · Source date: